Versantis is a clinical-stage pharmaceutical company that aims to revolutionize the care of patients with liver and rare pediatric diseases. Founded in 2015, the company's mission is to provide multiorgan support for rare pediatric and acute liver diseases. Versantis has recently received a significant investment of Fr.475.00K in the form of a grant from Innosuisse, indicating a strong interest in the company's innovative approach. The company focuses on addressing unmet medical needs in emergency care, particularly aiming to support acute decompensations of cirrhosis and save infants born with rare genetic disorders. Versantis operates within the health care and pharmaceutical industries, positioning itself as a key player in advancing treatment options for these critical medical conditions.
Versantis
Multiorgan support for rare pediatric and acute liver diseases
Zurich, Switzerland
2 employees
Grant
Total: $21.11M
Health Care, Health and Wellness +1
General Information
Zurich, Switzerland
BounceWatch is an independent company data service, not affiliated with Versantis. To contact Versantis, visit versantis.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Versantis compare?
A PDF of Versantis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Versantis soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
Switzerland Market
Health Care
About Versantis
Business keywords: Pharmaceutical company, Orphan medicines, Liver diseases, Rare pediatric diseases, Acute liver disease, Clinical-stage, Emergency care, Multiorgan support, Genetic disorders, Preventive therapies, Rare indications, Drug development, Orphan Drug Designation, Swiss pharmaceutical company
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | Fr.475.00K | 1 |
|
13 Apr 2022 |
| Series B | Fr.16.00M | 6 |
|
18 Sep 2019 |
| Series A | Fr.4.40M | 6 |
|
29 Mar 2017 |
| Non Equity Assistance | Fr.100.00K | 1 |
|
02 Nov 2016 |
| Seed Round | Fr.100.00K | 1 |
|
21 Jan 2015 |
| Grant | Fr.20.00K | 1 |
|
13 Aug 2014 |
| Non Equity Assistance | Undisclosed | 1 |
VentureOut
|
18 Jun 2014 |
| Grant | Fr.10.00K | 1 |
|
04 Mar 2014 |
Versantis Alternatives & Competitors
View All Alternatives
Creating transformative medicine for people with rare liver disease.
Exclusively dedicated to pioneering non-opioid pain solutions for serious rare diseases with high un...
Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases
FAQ About Versantis
Source: BounceWatch company record for Versantis, https://bouncewatch.com/company/versantis, updated 12 September 2024. When citing, please name BounceWatch and link this page.
